Efficacy of 1% clotrimazole cream versus 2% sertaconazole cream in the management of seborrheic dermatitis: A randomized controlled trial

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Antifungals are regarded as one of the first line agents in the management of seborrheic dermatitis (SD). However, the data on head to head comparison among various antifungal agents is deplete and is required to broaden the number of first line agents that can be used in SD treatment.

Aim: To compare the efficacy of 1% clotrimazole cream with 2% sertaconazole cream in the management of SD.

Methods: 60 patients of SD were included and divided into 2 groups. The first group (n = 30) received topical 2% sertoconazole cream for twice a day application for four weeks. The other group (n = 30) received 1% clotrimazole cream applied similarly for 4 weeks. The patients were assessed by an independent dermatologist for response or any side effects due to the medications used at 0 (baseline), 2 and 4 weeks. Subjective sebum production, Scalp and/or facial pruritus, scaling, erythema, SD severity index (SI), and patient satisfaction were used in the final efficacy outcome.

Results: Out of the total 60 patients, 65% (39/60) and 35% (21/60) were females and males respectively with age ranging from 6–58 years (mean age: 32.88 ± 12.68 years). 45% (27/60) had generalized and 55% (33/60) had localized disease. The severity of SD changed from moderate to mild in many patients after 4 weeks in both the groups, however, the difference was statistically significant only in the sertaconazole group (p = 0.007). 90% (27/30) and 53.4% (16/30) patients had good level of satisfaction in the sertaconazole and clotrimazole group on 28TH day. The relation was statistically significant only in the seratconazole group (p = 0.006). Subjective sebum production, pruritus, scaling and erythema reduced in both the groups. The follow-up period of 1-month post completion of therapy didn’t show any relapse in either of the groups.

Conclusion: Both topical 1% clotrimazole cream and topical 2% sertaconazole cream may be regarded as effective therapies in SD with topical 2% seratconazole cream performing better as compared to topical 1% clotrimazole cream in terms of patient efficacy and acceptability by the patients.

Full Text

Restricted Access

About the authors

R. Kothari

Department of Dermatology, Armed Forces Medical College

Email: mohamad.goldust@usb.ch
India, Pune

R Sadoughifar

University of Rome G. Marconi; Bidarskincenter

Email: mohamad.goldust@usb.ch
Italy, Rome; Tehran, Iran;

Torello Lotti

University of Studies Guglielmo Marconi

Email: Professor@torellolotti.it
Italy, Rome

Mohamad Goldust

University of Studies Guglielmo Marconi; Department of Dermatology of University Hospital Basel

Author for correspondence.
Email: mohamad.goldust@usb.ch

MD

Italy, Rome; Basel, Switzerland

References

  1. Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4(5):32-8.
  2. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):343-51.
  3. Palamaras I, Kyriakis KP, Stavrianeas NG. Seborrheic dermatitis: lifetime detection rates. J Eur Acad Dermatol Venereol. 2012;26(4):524-6.
  4. Picardo M, Cameli N. Seborrheic dermatitis. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, eds. Evidence-Based Dermatology. Blackwell Publishing; 2008:164-70.
  5. Adalsteinsson JA, Kaushik S, Muzumdar S, Guttman-Yassky E, Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020;29(5):481-9.
  6. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology. 2004;208(2):89-93.
  7. Sampaio AL, Mameri AC, de Sousa Vargas TJ, Ramos-e-Silva M, Nunes AP, da Silva Carneiro SC. Seborrheic dermatitis. An Bras Dermatol. 2011;86(6):1061-71.
  8. Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: past, present and future. J Appl Microbiol. 2014;117(3):611-7.
  9. Khatter NJ, Khan MAB. Clotrimazole. Review. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan.
  10. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;(5):CD008138.
  11. Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res. 2006;298(4):191-9.
  12. Balighi K, Ghodsi SZ, Daneshpazhooh M, Ghale-Baghi S, Nasimi M, Azizpour A. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial. Int J Womens Dermatol. 2017;3(2):107-10.
  13. Goldust M, Rezaee E, Masoudnia S, Raghifar R. Clinical study of sertaconazole 2% cream vs. hydrocortisone 1% cream in the treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(3):119-23.
  14. Dae Hun Suh. Seborrheic dermatitis. In: Kang S, Amgai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, eds. Fitzpatrick’s Dermatology. Part I. 9th ed. McGraw Hill; 2019:428-37.
  15. Kyung Sook Kim, Shin MK, Ahn JJ, Haw CR, Hun Kuk Park. A comparative study of hair shafts in scalp psoriasis and seborrheic dermatitis using atomic force microscopy. Skin Res Technol. 2013;19(1):e60-4.
  16. Wikramanayake TC, Borda LJ, Miteva M, Paus R. Seborrheic dermatitis – looking beyond Malassezia. Exp Dermatol. 2019;28(9):991-1001.
  17. Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol. 2015;3(2):10.13188/2373-1044.1000019.
  18. Augustin M, Kirsten N, Korber A, Wilsmann-Theis D, Itschert G, Staubach-Renz P, et al. Prevalence, predictors and comorbidity of dry skin in the general population. J Eur Acad Dermatol Venereol. 2019;33(1):147-50.
  19. Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM.; Danish Society of Dermatology. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm. Venereol. 2015;95(1):12-9.
  20. McKeny PT, Nessel TA, Zito PM. Antifungal Antibiotics. StatPearls [Internet]. 2019. Treasure Island (FL): StatPearls Publishing; 2020 Jan.
  21. Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(1):25-9.
  22. Attarzadeh Y, Asilian A, Shahmoradi Z, Adibi N. Comparing the efficacy of Emu oil with clotrimazole and hydrocortisone in the treatment of seborrheic dermatitis: a clinical trial. J Res Med Sci. 2013;18(6):477-81.
  23. Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream. Ann Parasitol. 2013;59(2):73-7.
  24. Goldust M, Rezaee E, Raghifar R. Treatment of seborrheic dermatitis: comparison of sertaconazole 2% cream versus pimecrolimus 1% cream. Irish J Med Sci. 2013;182(4):703-6.
  25. Lotti T, Goldust M, Rezaee E. Treatment of seborrheic dermatitis, comparison of sertaconazole 2% cream versus ketoconazole 2% cream. J Dermatol Treat. 2013 May 6. doi: 10.3109/09546634.2013.777154. Online ahead of print.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies